Brain Res 1036:16 Ghezzi P, Di Simplicio P (2007) Glutathionylation pathways in drug response
When people on GLP-1 medications eat significantly less food, they often unintentionally consume very little fiber
These effects are usually manageable, but you should contact your clinician if symptoms are severe, persistent, or interfere with daily life
9,10 These actions change eating behaviour: the anticipatory food reward for looking forward to eating certain (delicious) foods decreases, while consummatory food reward (the pleasure offered by eating) increases
2 Kidney Disease Risk Reduction In addition, the FDA has approved semaglutide (Ozempic) to slow the progression of kidney disease and reduce the risk of kidney failure, making it the most widely indicated GLP-1 drug